- QuantiFERON-TB Gold test devices are essential diagnostic tools used for detecting latent tuberculosis (TB) infections by measuring the release of interferon-gamma in response to TB-specific antigens. These tests are widely used in clinical practice to identify asymptomatic TB carriers, allowing for early intervention and prevention of active TB transmission
- The demand for these tests is significantly driven by the global rise in TB cases, increasing awareness of latent TB, and the push for TB elimination by organizations such as the WHO. Technological advancements in interferon-gamma release assays (IGRAs), including improved sensitivity and specificity, further support market growth. The shift towards precision diagnostics and increasing public health initiatives also contribute to the expanding market
- North America is expected to dominate the QuantiFERON-TB Gold test market with 45.6% market share, driven by advanced healthcare infrastructure, widespread adoption of cutting-edge medical technologies, and the strong presence of key market players
- Asia-Pacific is expected to be the fastest growing region in the QuantiFERON-TB Gold test market, with 25.1% market share, driven by rapid healthcare infrastructure expansion, rising awareness about neurological disorders, and increasing healthcare spending
- Interferon Gamma Release Assay (IGRA) segment is expected to dominate the QuantiFERON-TB Gold test market, holding 41.87% market share. IGRAs, including the QuantiFERON-TB Gold Plus, are the most widely used TB diagnostic tests due to their superior specificity and sensitivity compared to traditional Tuberculin Skin Tests (TST), particularly in individuals vaccinated with Bacille Calmette-Guérin (BCG)
